Antibody that blocks Omicron, other Covid variants identified by scientists

A group of scientists in the US has identified an antibody that appears to block infection by all dominant variants of the virus that causes Covid-19, including Omicron

Omicron
Photo: Bloomberg
IANS New York
2 min read Last Updated : Apr 08 2023 | 7:12 PM IST

A group of scientists in the US has identified an antibody that appears to block infection by all dominant variants of the virus that causes Covid-19, including Omicron.

The discovery could lead to more potent vaccines and new antibody-based treatments.

In a study published in the Journal of Clinical Investigation, senior author Dr Patrick Wilson from Weill Cornell Medicine at the University of Wisconsin-Madison and his colleagues, tested antibodies derived from patient blood samples against successive versions of the virus that emerged during the pandemic.

One of these proteins, dubbed S728-1157, proved highly effective at neutralising not only older variants but also seven subtypes of Omicron.

The team also had researchers from Scripps Research and the University of Chicago.

"The pandemic is winding down, but the virus is around for the long haul. If not well controlled, it could cause annual epidemics," Dr Wilson said. "This antibody and the insight it provides could help us avoid yearly surges of Covid-19 or if there is another coronavirus pandemic."

Dr. Wilson's group analysed antibody-producing cells to find those that latched on to the virus's spike protein, which it uses to get into human cells.

Another study author Dr Siriruk Changrob tested the antibodies they found against 12 variants of SARS-CoV-2, including the original version of the virus.

One antibody, called S728-1157, stood out for its ability to interfere with Omicron.

Their results suggest that S728-1157 could become the basis for a much-needed alternative to conventional antibody-based treatments.

The research could also guide the design of new vaccines that rely on the spike protein to stimulate the production of antibodies, said the study.

--IANS

na/svn/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronUnited StatesScientists

First Published: Apr 08 2023 | 7:12 PM IST

Next Story